DD01 is a Unique Dual Agonist that Rapidly Reduces Liver Fat, Improves Metabolic Health, & is More Effective than Diet or an Incretin Alone
Time: 1:20 pm
day: Conf Day 1 Track 2 PM
Details:
- DD01 is well tolerated at doses that rapidly reduce hepatic steatosis and improve glucose tolerance in obese diabetics with diabetes and MASLD
- Mechanistic studies in animals reveal DD01 is more effective than calorie restriction or treatment with a GLP-1 in reducing liver fat and reveal concurrent improvements in clinical markers of MASH resolution that are not matched by equivalent doses of semaglutide
- The unique therapeutic profile of DD01, a pegylated GLP1/Glucagon receptor agonist, show it provides rapid reductions in hepatic steatosis that are attributable to glucagon and can be uncoupled from the more gradual effects of calorie restriction and weight loss
